Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?

Postow, M.A.

Clinical Advances in Hematology and Oncology H&o 16(5): 353-355

2018


ISSN/ISBN: 1543-0790
PMID: 29851931
Document Number: 694977

Document emailed within 1 workday
Secure & encrypted payments